



an Open Access Journal by MDPI

## 10th Anniversary of Biomedicines—Sepsis: Diagnostics and Therapeutics

Guest Editors:

### Dr. Tsukasa Nakamura

Division of Nephrology,  
Department of Internal Medicine,  
Kashiwa Forest Clinic, Kashiwa,  
Chiba, Japan

### Dr. Eiichi Sato

Division of Nephrology,  
Department of Internal Medicine,  
Shinmatsudo Central General  
Hospital, Matsudo, Chiba, Japan

Deadline for manuscript  
submissions:

**closed (15 November 2022)**

### Message from the Guest Editors

The recently-modified Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) defines sepsis as a “life-threatening organ dysfunction caused by a dysregulated host response to infection” and septic shock as “a subset of sepsis in which particularly profound circulatory, cellular, and metabolic abnormalities are associated with a greater risk of mortality than with sepsis alone”. Sepsis-3 guidelines still prompt debate and discussion, such as the requirement for a serum lactate level to diagnose septic shock, or use of the quick sepsis-related organ failure assessment (SOFA) score in the diagnosis of sepsis. Further detailed verification is required for reevaluation and future revision of Sepsis-3.

This Special Issue of the *Biomedicines* will focus on sepsis, and report new insights into epidemiology, pathophysiology, diagnosis, biomarkers, and treatment. In addition, other morbidities and renal replacement therapy, including acute kidney injury and hemodiafiltration, are associated with sepsis, and submissions dealing with these conditions are welcome.



[mdpi.com/si/106354](https://mdpi.com/si/106354)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
X@Biomed\_MDPI